Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
1 May 24
8-K
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
1 May 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
10-K
2023 FY
Annual report
9 Feb 24
8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
7 Feb 24
8-K
Other Events
13 Nov 23
8-K
Other Events
9 Nov 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
31 Oct 23
8-K
Other Events
6 Oct 23
8-K
Other Events
5 Oct 23
8-K
Other Events
12 Sep 23
S-8
Registration of securities for employees
1 Aug 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
1 Aug 23
8-K
Departure of Directors or Certain Officers
13 Jul 23
8-K
Departure of Directors or Certain Officers
11 Jul 23
8-K
Departure of Directors or Certain Officers
19 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
3 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
DEFA14A
Additional proxy soliciting materials
5 Apr 23
DEF 14A
Definitive proxy
5 Apr 23
8-K
Other Events
28 Mar 23
8-K
Other Events
23 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
10 Feb 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results
6 Feb 23
8-K
Entry into a Material Definitive Agreement
9 Jan 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
8-K
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results
1 Nov 22
8-K
Regulation FD Disclosure
30 Aug 22
S-8
Registration of securities for employees
4 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Other Events
31 May 22
8-K
Neurocrine Biosciences Announces Repurchase of Convertible Notes
24 May 22
Latest ownership filings
4
Ingrid Delaet
8 May 24
4
ERIC BENEVICH
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Ingrid Delaet
3 Apr 24
4
Ingrid Delaet
25 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
4
ERIC BENEVICH
15 Mar 24
4
GEORGE J MORROW
15 Mar 24
4
RICHARD F POPS
15 Mar 24
4
Ingrid Delaet
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
RICHARD F POPS
12 Mar 24
4
Ingrid Delaet
12 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Ingrid Delaet
29 Feb 24
4
ERIC BENEVICH
29 Feb 24
4
Leslie V Norwalk
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
4
RICHARD F POPS
22 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
4
EIRY ROBERTS
15 Feb 24
4
Jude Onyia
15 Feb 24
4
Darin Lippoldt
15 Feb 24
4
KEVIN CHARLES GORMAN
15 Feb 24
4
Kyle Gano
15 Feb 24
4
Ingrid Delaet
15 Feb 24
4
Julie Cooke
15 Feb 24
4
David W. Boyer
15 Feb 24
4
ERIC BENEVICH
15 Feb 24
4
MATT ABERNETHY
15 Feb 24
4
KEVIN CHARLES GORMAN
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24